Jean-Pascal Machiels

18PUBLICATIONS
172CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Pharmaceutical delivery technologies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Mar 23, 2026
Molecular and Immune Landscape of Recurrent and/or Distant Metastatic Squamous Cell Carcinoma of the Head and Neck: An EORTC/IMMUCAN Project.

Athénaïs van der Elst, Daniel Herrero-Saboya, Lucas Michon

|Feb 10, 2026
Genomic and Immune Landscape of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Progressing on Anti-PD-1 Treatment.

Athénaïs van der Elst, Daniel Herrero-Saboya, Lucas Michon

|Aug 11, 2025
Tumor-Informed ctDNA Assay to Predict Outcome in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with PD-1 Inhibitor.

Natasha Honoré, George Laliotis, Vasily N Aushev

|Jun 13, 2025
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC.

Jean-Pascal Machiels, Jérôme Fayette, Robert Haddad

|Apr 29, 2025
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Jérôme Fayette, Lisa Licitra, Kevin Harrington

|Apr 18, 2025
STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC.

Nabil F Saba, Kevin Harrington, Lisa Licitra

Pageof 3

Frequent Collaborators

4 joint publications

Rachel Galot

3 joint publications

Paolo Bossi

3 joint publications

Kevin J Harrington

3 joint publications

Sandra Schmitz